A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children

Akiko Kada; Reiji Fukano; Tetsuya Mori; Michi Kamei; Fumiko Tanaka; Junichi Ueyama; Masahiro Sekimizu; Tomoo Osumi; Takeshi Mori; Yuhki Koga; Kentaro Ohki; Naoto Fujita; Tetsuo Mitsui; Akiko M. Saito; Hiroya Hashimoto; Ryoji Kobayashi

A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children

Akiko Kada, Reiji Fukano, Tetsuya Mori, Michi Kamei, Fumiko Tanaka, Junichi Ueyama, Masahiro Sekimizu, Tomoo Osumi, Takeshi Mori, Yuhki Koga, Kentaro Ohki, Naoto Fujita, Tetsuo Mitsui, Akiko M. Saito, Hiroya Hashimoto, Ryoji Kobayashi

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/mx²/day) for five days plus melphalan (70 mg/mx²/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.

Original language	English
Pages (from-to)	89-94
Number of pages	6
Journal	Acta Medica Okayama
Volume	74
Issue number	1
Publication status	Published - 2020
Externally published	Yes

All Science Journal Classification (ASJC) codes

General Biochemistry,Genetics and Molecular Biology

Fingerprint

Dive into the research topics of 'A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children'. Together they form a unique fingerprint.

Cite this

Kada, A., Fukano, R., Mori, T., Kamei, M., Tanaka, F., Ueyama, J., Sekimizu, M., Osumi, T., Mori, T., Koga, Y., Ohki, K., Fujita, N., Mitsui, T., Saito, A. M., Hashimoto, H., & Kobayashi, R. (2020). A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children. Acta Medica Okayama, 74(1), 89-94.

@article{a110f0b2047e47a8ab456fbfd768c909,

title = "A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children",

abstract = "No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/mx2/day) for five days plus melphalan (70 mg/mx2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.",

author = "Akiko Kada and Reiji Fukano and Tetsuya Mori and Michi Kamei and Fumiko Tanaka and Junichi Ueyama and Masahiro Sekimizu and Tomoo Osumi and Takeshi Mori and Yuhki Koga and Kentaro Ohki and Naoto Fujita and Tetsuo Mitsui and Saito, {Akiko M.} and Hiroya Hashimoto and Ryoji Kobayashi",

note = "Publisher Copyright: {\textcopyright} 2020 by Okayama University Medical School.",

year = "2020",

language = "English",

volume = "74",

pages = "89--94",

journal = "Acta Medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "1",

}

Kada, A, Fukano, R, Mori, T, Kamei, M, Tanaka, F, Ueyama, J, Sekimizu, M, Osumi, T, Mori, T, Koga, Y, Ohki, K, Fujita, N, Mitsui, T, Saito, AM, Hashimoto, H & Kobayashi, R 2020, 'A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children', Acta Medica Okayama, vol. 74, no. 1, pp. 89-94.

A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children. / Kada, Akiko; Fukano, Reiji; Mori, Tetsuya et al.
In: Acta Medica Okayama, Vol. 74, No. 1, 2020, p. 89-94.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children

AU - Kada, Akiko

AU - Fukano, Reiji

AU - Mori, Tetsuya

AU - Kamei, Michi

AU - Tanaka, Fumiko

AU - Ueyama, Junichi

AU - Sekimizu, Masahiro

AU - Osumi, Tomoo

AU - Mori, Takeshi

AU - Koga, Yuhki

AU - Ohki, Kentaro

AU - Fujita, Naoto

AU - Mitsui, Tetsuo

AU - Saito, Akiko M.

AU - Hashimoto, Hiroya

AU - Kobayashi, Ryoji

PY - 2020

Y1 - 2020

N2 - No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/mx2/day) for five days plus melphalan (70 mg/mx2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.

AB - No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/mx2/day) for five days plus melphalan (70 mg/mx2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.

UR - http://www.scopus.com/inward/record.url?scp=85097004338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097004338&partnerID=8YFLogxK

M3 - Article

C2 - 32099255

AN - SCOPUS:85097004338

SN - 0386-300X

VL - 74

SP - 89

EP - 94

JO - Acta Medica Okayama

JF - Acta Medica Okayama

IS - 1

ER -

A Multicenter, Open-label, Clinical Trial to Assess the Effectiveness and Safety of Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-intensity Conditioning in Relapsed/refractory Anaplastic Large-cell Lymphoma in Children

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Fingerprint

Cite this